Research Paper Advance Articles

Platelet-derived biomaterials-mediated improvement of bone injury through migratory ability of embryonic fibroblasts: in vitro and in vivo evidence

Schematic of in vitro and in vivo experimental protocol representing migration and osteogenic potential of platelet-derived biomaterials (PDB) containing TGF-β-1 on mouse embryonic fibroblasts (MEFs) to improve bone injury. During in vitro assay, the osteogenic potential was evaluated through expression of markers RUNX2, OPN, and OCN; whereas, migratory ability was determined by expression levels of FAK, p-FAK, Scr, Vimentin, and E-cadherin. Further, after PDB treatment of bone injury in FVB mice, the bone mineral density (BMD) of femur was noted, while cellular migration was assessed via SDF-1, GFP, OCN to evaluate bone injury improvement.

Figure 1. Schematic of in vitro and in vivo experimental protocol representing migration and osteogenic potential of platelet-derived biomaterials (PDB) containing TGF-β-1 on mouse embryonic fibroblasts (MEFs) to improve bone injury. During in vitro assay, the osteogenic potential was evaluated through expression of markers RUNX2, OPN, and OCN; whereas, migratory ability was determined by expression levels of FAK, p-FAK, Scr, Vimentin, and E-cadherin. Further, after PDB treatment of bone injury in FVB mice, the bone mineral density (BMD) of femur was noted, while cellular migration was assessed via SDF-1, GFP, OCN to evaluate bone injury improvement.